{"success":true,"data":{"pressRelease":{"id":"127073","rtpr_id":"nNFC2yXDLk","ticker":"BUX","exchange":"","all_tickers":["BUX"],"title":"BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy","author":"Newsfile Corp","published_at":"2026-08-25T12:30:14.788Z","article_body":"Five peer-reviewed studies published in nine months independently confirm high\naccuracy, robust panel optimization, and commercial viability of BioMark's\nblood-based assay.\n\nVancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark\nDiagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) (\"BioMark\" or the\n\"Company\"), a leading developer of liquid biopsy technologies focused on the\nearly detection of lung cancer through metabolomics, is pleased to announce\ncrucial updates reinforcing the clinical translation of its liquid biopsy\ntechnology platform for early non-small cell lung cancer (NSCLC) screening and\nrisk stratification with the publication of two new peer-reviewed scientific\npapers. Published within days of each other in top international scientific\njournals, these papers bring the Company's total to five high-impact\npublications over the past nine months, highlighting the rapid clinical\ntranslation and de-risking of its platform.\n\nThe newly published research highlights BioMark's integration of artificial\nintelligence (AI) and machine learning (ML) to construct smaller,\ncost-effective, and highly interpretable diagnostic models that isolate true\ncancer signals from real-world confounding factors such as smoking status.\n\nThe first study, published in Biomedicines on August 18, 2026, introduces\nSemantic Embedding-based Feature Augmentation (SEFA), a framework leveraging a\nbiomedical language model to blend established biological knowledge directly\ninto predictive analytics. This compact, 24-feature model achieved a test\nROC-AUC of 96.9% and 94.4% accuracy in distinguishing lung cancer cases from\ncontrols within a cohort of 800 participants, outperforming standard\nmetabolite-only models.\n\nThe second study, published in the International Journal of Molecular Sciences\non August 17, 2026, evaluated a 1,038-patient cohort to decouple\ntobacco-exposure signals from underlying cancer biology using statistical\ndecomposition and four independent ML feature-selection algorithms. The\nresearchers successfully deployed a refined 19-metabolite panel that matched\noriginal never-smoker diagnostic accuracy (AUC ≈ 0.91 vs. 0.895),\nsignificantly reducing assay complexity and testing costs while maintaining\nhigh diagnostic power.\n\n\"Capturing this level of scientific interest and engagement validates both the\nmethodological rigor and commercial direction of our analytics platform.\" said\nDr. Jean-François Haince, Chief Scientific Officer at BioMark and co-author\non the publication. \"Together, these published findings validate the\nfundamental science behind BioMark's technology and underscores how rapidly we\nare tackling key diagnostic challenges, such as eliminating smoking bias to\nleveraging biomedical language models for richer biological insights. These\npeer-reviewed milestones directly confirm the precision, performance, and\ncost-effectiveness of our blood test as we continue to de-risk and accelerate\nour path toward commercial deployment.\"\n\nThe ongoing spotlight from the global scientific community highlights\nBioMark's growing leadership in applying artificial intelligence and machine\nlearning to lung cancer detection. The Company continues to leverage this\nstrong scientific cadence to build commercial momentum, execute external\nvalidation trials, and advance regulatory submission efforts across target\nNorth American markets.\n\nAbout BioMark Diagnostics Inc.\n\nBioMark Diagnostics Inc. is a precision diagnostics company dedicated to the\nearly detection of cancer through the analysis of metabolic biomarkers and\nmachine learning algorithms. The Company's platform leverages proprietary\nmetabolomic profiling technology to identify individuals with early-stage\ncancer through a simple, minimally invasive blood draw. BioMark is advancing\nits commercial screening panel for lung cancer toward market entry and\nregulatory approval, operating out of Canada with an expanding network of\ninternational clinical and research collaborations.\n\nFurther information about BioMark Diagnostic Inc. is available under its\nprofile on the SEDAR+ website www.sedarplus.ca and the CSE website\nhttps://thecse.com/.\n\nFor further information on BioMark Diagnostic Inc., please contact:\nRashid Ahmed Bux\nPresident & CEO\nBioMark Diagnostics Inc.\nTel. 604-370-0779\nEmail: info@biomarkdiagnostics.com\n\nForward-Looking Information:\n\nThis press release may include forward-looking information within the meaning\nof Canadian securities legislation, concerning the business of BioMark\nDiagnostics Inc. Forward-Looking information is based on certain key\nexpectations and assumptions made by the management of the company. Although\nit believes that the expectations and assumptions on which such\nforward-looking information is based are reasonable, undue reliance should not\nbe placed on the forward-looking information because BioMark Diagnostics Inc.\ncan give no assurance that they will prove to be correct. Forward-Looking\nstatements contained in this press release are made as of the date of this\npress release. BioMark Diagnostics Inc. disclaims any intent or obligation to\nupdate publicly any forward-looking information, whether as a result of new\ninformation, future events, or results or otherwise, other than as required by\napplicable securities laws.\n\nThe CSE has not reviewed, approved, or disapproved of the content of this\npress release.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311231","article_body_html":"","raw_payload":{"data":{"id":"nNFC2yXDLk","title":"BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy","author":"Newsfile Corp","ticker":"BUX","created":"2026-08-25T12:30:14.788Z","tickers":["BUX"],"exchange":"","article_body":"Five peer-reviewed studies published in nine months independently confirm high\naccuracy, robust panel optimization, and commercial viability of BioMark's\nblood-based assay.\n\nVancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark\nDiagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) (\"BioMark\" or the\n\"Company\"), a leading developer of liquid biopsy technologies focused on the\nearly detection of lung cancer through metabolomics, is pleased to announce\ncrucial updates reinforcing the clinical translation of its liquid biopsy\ntechnology platform for early non-small cell lung cancer (NSCLC) screening and\nrisk stratification with the publication of two new peer-reviewed scientific\npapers. Published within days of each other in top international scientific\njournals, these papers bring the Company's total to five high-impact\npublications over the past nine months, highlighting the rapid clinical\ntranslation and de-risking of its platform.\n\nThe newly published research highlights BioMark's integration of artificial\nintelligence (AI) and machine learning (ML) to construct smaller,\ncost-effective, and highly interpretable diagnostic models that isolate true\ncancer signals from real-world confounding factors such as smoking status.\n\nThe first study, published in Biomedicines on August 18, 2026, introduces\nSemantic Embedding-based Feature Augmentation (SEFA), a framework leveraging a\nbiomedical language model to blend established biological knowledge directly\ninto predictive analytics. This compact, 24-feature model achieved a test\nROC-AUC of 96.9% and 94.4% accuracy in distinguishing lung cancer cases from\ncontrols within a cohort of 800 participants, outperforming standard\nmetabolite-only models.\n\nThe second study, published in the International Journal of Molecular Sciences\non August 17, 2026, evaluated a 1,038-patient cohort to decouple\ntobacco-exposure signals from underlying cancer biology using statistical\ndecomposition and four independent ML feature-selection algorithms. The\nresearchers successfully deployed a refined 19-metabolite panel that matched\noriginal never-smoker diagnostic accuracy (AUC ≈ 0.91 vs. 0.895),\nsignificantly reducing assay complexity and testing costs while maintaining\nhigh diagnostic power.\n\n\"Capturing this level of scientific interest and engagement validates both the\nmethodological rigor and commercial direction of our analytics platform.\" said\nDr. Jean-François Haince, Chief Scientific Officer at BioMark and co-author\non the publication. \"Together, these published findings validate the\nfundamental science behind BioMark's technology and underscores how rapidly we\nare tackling key diagnostic challenges, such as eliminating smoking bias to\nleveraging biomedical language models for richer biological insights. These\npeer-reviewed milestones directly confirm the precision, performance, and\ncost-effectiveness of our blood test as we continue to de-risk and accelerate\nour path toward commercial deployment.\"\n\nThe ongoing spotlight from the global scientific community highlights\nBioMark's growing leadership in applying artificial intelligence and machine\nlearning to lung cancer detection. The Company continues to leverage this\nstrong scientific cadence to build commercial momentum, execute external\nvalidation trials, and advance regulatory submission efforts across target\nNorth American markets.\n\nAbout BioMark Diagnostics Inc.\n\nBioMark Diagnostics Inc. is a precision diagnostics company dedicated to the\nearly detection of cancer through the analysis of metabolic biomarkers and\nmachine learning algorithms. The Company's platform leverages proprietary\nmetabolomic profiling technology to identify individuals with early-stage\ncancer through a simple, minimally invasive blood draw. BioMark is advancing\nits commercial screening panel for lung cancer toward market entry and\nregulatory approval, operating out of Canada with an expanding network of\ninternational clinical and research collaborations.\n\nFurther information about BioMark Diagnostic Inc. is available under its\nprofile on the SEDAR+ website www.sedarplus.ca and the CSE website\nhttps://thecse.com/.\n\nFor further information on BioMark Diagnostic Inc., please contact:\nRashid Ahmed Bux\nPresident & CEO\nBioMark Diagnostics Inc.\nTel. 604-370-0779\nEmail: info@biomarkdiagnostics.com\n\nForward-Looking Information:\n\nThis press release may include forward-looking information within the meaning\nof Canadian securities legislation, concerning the business of BioMark\nDiagnostics Inc. Forward-Looking information is based on certain key\nexpectations and assumptions made by the management of the company. Although\nit believes that the expectations and assumptions on which such\nforward-looking information is based are reasonable, undue reliance should not\nbe placed on the forward-looking information because BioMark Diagnostics Inc.\ncan give no assurance that they will prove to be correct. Forward-Looking\nstatements contained in this press release are made as of the date of this\npress release. BioMark Diagnostics Inc. disclaims any intent or obligation to\nupdate publicly any forward-looking information, whether as a result of new\ninformation, future events, or results or otherwise, other than as required by\napplicable securities laws.\n\nThe CSE has not reviewed, approved, or disapproved of the content of this\npress release.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/311231"},"type":"article","timestamp":"2026-08-25T12:30:14.872639198Z","server_sent_at_ms":1787661014872},"received_at":"2026-08-25T12:30:14.922Z","source_url":"https://www.newsfilecorp.com/release/311231"},"analysis":{"id":"116001","press_release_id":"127073","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"BioMark Diagnostics announced that five peer-reviewed studies published over the last nine months have independently confirmed the accuracy and commercial viability of its liquid biopsy platform for early lung cancer screening.\n\nTwo new studies published in Biomedicines and the International Journal of Molecular Sciences demonstrated AI-driven models achieving 96.9% ROC-AUC and 94.4% accuracy, successfully isolating cancer signals from smoking-related confounding factors.\n\nThe company intends to leverage these findings to accelerate external validation trials and regulatory submission efforts across North American markets.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Independent peer validation with high accuracy scores de-risks the path to commercialization."},"keyFigures":{"customDimensions":{"study1_roc_auc":"96.9%","study1_accuracy":"94.4%","study1_features":24,"studies_published":5,"study1_cohort_size":800,"study2_cohort_size":1038,"study2_auc_comparison":"0.91 vs 0.895","publication_period_months":9,"study2_metabolite_panel_size":19}},"quotedText":"Capturing this level of scientific interest and engagement validates both the methodological rigor and commercial direction of our analytics platform.","namedEntities":{"people":[{"name":"Dr. Jean-François Haince","role":"Chief Scientific Officer"},{"name":"Rashid Ahmed Bux","role":"President & CEO"}],"products":["SEFA (Semantic Embedding-based Feature Augmentation)","liquid biopsy technology","metabolomic profiling technology"],"companies":[{"name":"BioMark Diagnostics Inc.","ticker":"BUX"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Publication of two additional peer-reviewed papers validates the platform's high diagnostic accuracy (96.9% ROC-AUC) and ability to reduce confounding factors, marking a significant de-risking milestone for a development-stage diagnostic company."},"tickerRelevance":{"others":[],"primary":"BUX"},"globalImportance":20,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro_cap","eventGravity":"clinical_validation"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"BioMark Diagnostics announced that five peer-reviewed studies published over the last nine months have independently confirmed the accuracy and commercial viability of its liquid biopsy platform for early lung cancer screening.\n\nTwo new studies published in Biomedicines and the International Journal of Molecular Sciences demonstrated AI-driven models achieving 96.9% ROC-AUC and 94.4% accuracy, successfully isolating cancer signals from smoking-related confounding factors.\n\nThe company intends to leverage these findings to accelerate external validation trials and regulatory submission efforts across North American markets.","key_figures":{"customDimensions":{"study1_roc_auc":"96.9%","study1_accuracy":"94.4%","study1_features":24,"studies_published":5,"study1_cohort_size":800,"study2_cohort_size":1038,"study2_auc_comparison":"0.91 vs 0.895","publication_period_months":9,"study2_metabolite_panel_size":19}},"named_entities":{"people":[{"name":"Dr. Jean-François Haince","role":"Chief Scientific Officer"},{"name":"Rashid Ahmed Bux","role":"President & CEO"}],"products":["SEFA (Semantic Embedding-based Feature Augmentation)","liquid biopsy technology","metabolomic profiling technology"],"companies":[{"name":"BioMark Diagnostics Inc.","ticker":"BUX"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-25T14:14:59.073Z","global_importance":20,"audience_relevance":20,"importance_components":{"tickerTier":"micro_cap","eventGravity":"clinical_validation"}},"durationMs":123538,"modelName":"glm-4.7"}}